GLP-3 RTA [Triple G] - 40mg
GLP-3 RTA [Triple G] 40mg. Used to support weight management, appetite control, reduced food cravings, and metabolic health. Lab tested, discreetly shipped across Canada.
GLP-3 RTA [Triple G] 40mg. Used to support weight management, appetite control, reduced food cravings, and metabolic health. Lab tested, discreetly shipped across Canada.
GLP-3 RTA (Triple G) is a triple incretin receptor agonist simultaneously targeting glucagon like peptide-1 (GLP-1), glucose dependent insulinotropic polypeptide (GIP), and glucagon receptors. The most advanced incretin based research compound in CSD’s metabolic peptide range. iLab Pharma’s 40mg formulation delivers a lower concentration presentation than the Hudson Science 50mg and 60mg GLP-3 RTA variants as a lyophilized vial, providing researchers with an accessible entry point into triple incretin agonist research or a practical option for shorter duration protocols and initial compound evaluation before committing to larger supply volumes.
The triple receptor mechanism of GLP-3 RTA remains consistent across all concentration presentations and manufacturers. GLP-1 receptor activation drives glucose dependent insulin secretion, glucagon suppression at the pancreas, and central nervous system satiety signaling. GIP receptor activation contributes complementary insulinotropic activity alongside adipose tissue metabolic effects and bone turnover research applications. Glucagon receptor co activation adds direct hepatic glucose output regulation, thermogenic energy expenditure stimulation through brown adipose tissue activation, and lipolytic activity in white adipose tissue. A third distinct pathway producing a synergistic metabolic response that has driven significant research interest in comparative receptor pathway studies examining the incremental contribution of glucagon co activation to the dual GIP/GLP-1 baseline.
CSD’s GLP-3 RTA range now spans three concentration options across two manufacturers: iLab Pharma 40mg, Hudson Science 50mg, and Hudson Science 60mg sitting above the dual GIP/GLP-1 agonist GLP-2 TRZ 20mg and GLP-2 TZ 15mg listings in receptor pathway complexity. Researchers selecting between Triple G presentations can choose based on protocol length, dose response requirements, and manufacturer preference. The 40mg iLab Pharma format suited to shorter protocols and initial evaluation, the 50mg Hudson Science format providing a mid range option, and the 60mg Hudson Science format supporting the most extended research timelines from a single vial supply.
iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and iLab Pharma’s GLP-3 RTA meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.
Commonly researched alongside dual incretin agonist compounds in comparative receptor pathway and metabolic activity studies. Browse CSD’s full peptide range for complete sourcing.
Just as ordered! Ordering process is quick and simple. The best part is shipping is generally quick. Product works as it should and the entire process is great!
GLP-3 RTA contains 40mg of RTA, an investigational peptide commonly described as a Triple G receptor agonist. RTA activates three metabolic hormone receptors: GIP, GLP-1, and glucagon within a single molecule. Research has focused on body weight regulation, appetite signaling, glucose metabolism, insulin sensitivity, energy expenditure, lipid metabolism, and broader cardiometabolic function.
RTA is called Triple G because it simultaneously activates the glucose dependent insulinotropic polypeptide (GIP), glucagon like peptide 1 (GLP-1), and glucagon receptors. GIP and GLP-1 are incretin pathways involved in glucose regulation, insulin response, and appetite signaling, while glucagon receptor activity contributes additional effects involving hepatic metabolism and energy expenditure. This three receptor profile distinguishes RTA from single and dual incretin agonists.
Semaglutide primarily activates the GLP-1 receptor, while tirzepatide activates both GIP and GLP-1 receptors. RTA activates GIP, GLP-1, and glucagon receptors simultaneously. The additional glucagon receptor activity gives RTA a distinct research profile involving energy expenditure, lipid metabolism, hepatic metabolism, appetite regulation, and glucose control.
RTA is being investigated extensively in clinical research involving obesity, body weight regulation, type 2 diabetes, glycemic control, and cardiometabolic health. Research has also examined changes in liver fat, lipid metabolism, appetite, insulin sensitivity, and other metabolic markers. Its triple GIP, GLP-1, and glucagon receptor mechanism is designed to combine complementary pathways involved in energy intake, glucose regulation, and energy expenditure.
Yes! This batch is HPLC tested to verify RTA identity and content accuracy at 40mg per vial. A certificate of analysis is available.
Price range: $479.00 through $4,311.00 (-10%)
Add to cart